123 related articles for article (PubMed ID: 24042242)
1. Metabolic monitoring of patients prescribed second-generation antipsychotics.
Dhamane AD; Martin BC; Brixner DI; Hudson TJ; Said Q
J Psychiatr Pract; 2013 Sep; 19(5):360-74. PubMed ID: 24042242
[TBL] [Abstract][Full Text] [Related]
2. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
[TBL] [Abstract][Full Text] [Related]
3. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
4. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics.
DelMonte MT; Bostwick JR; Bess JD; Dalack GW
J Clin Pharm Ther; 2012 Dec; 37(6):668-73. PubMed ID: 22845616
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of monitoring practices in patients on second generation antipsychotics.
Nguyen D; Brakoulias V; Boyce P
Australas Psychiatry; 2009 Aug; 17(4):295-9. PubMed ID: 19585292
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of Recommended Metabolic Laboratory Parameters Among Medicaid Recipients on Second-Generation Antipsychotics in Federally Qualified Health Centers.
Uzal NE; Chavez B; Kosirog ER; Billups SJ; Saseen JJ
Ann Pharmacother; 2018 Feb; 52(2):160-165. PubMed ID: 28884591
[TBL] [Abstract][Full Text] [Related]
8. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre.
Tarricone I; Casoria M; Gozzi BF; Grieco D; Menchetti M; Serretti A; Ujkaj M; Pastorelli F; Berardi D
BMC Psychiatry; 2006 Mar; 6():11. PubMed ID: 16542430
[TBL] [Abstract][Full Text] [Related]
9. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths.
Rubin DM; Kreider AR; Matone M; Huang YS; Feudtner C; Ross ME; Localio AR
JAMA Pediatr; 2015 Apr; 169(4):e150285. PubMed ID: 25844991
[TBL] [Abstract][Full Text] [Related]
10. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
11. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
12. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.
Moeller KE; Rigler SK; Mayorga A; Nazir N; Shireman TI
Schizophr Res; 2011 Mar; 126(1-3):117-23. PubMed ID: 21168994
[TBL] [Abstract][Full Text] [Related]
13. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
[TBL] [Abstract][Full Text] [Related]
14. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
15. Metabolic screening in children receiving antipsychotic drug treatment.
Morrato EH; Nicol GE; Maahs D; Druss BG; Hartung DM; Valuck RJ; Campagna E; Newcomer JW
Arch Pediatr Adolesc Med; 2010 Apr; 164(4):344-51. PubMed ID: 20368487
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: a retrospective cohort study.
Laundon W; Muzyk AJ; Gagliardi JP; Christopher EJ; Rothrock-Christian T; Jiang W
Gen Hosp Psychiatry; 2012; 34(4):380-4. PubMed ID: 22554429
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naïve French Canadian patients.
Roy G; Bedard A; Desmarais PA; Jourdain F; Allen S; Michaud D; Ben Amor L
J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):479-87. PubMed ID: 21186966
[TBL] [Abstract][Full Text] [Related]
18. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics.
Citrome L; Collins JM; Nordstrom BL; Rosen EJ; Baker R; Nadkarni A; Kalsekar I
J Clin Psychiatry; 2013 Dec; 74(12):1199-206. PubMed ID: 24434088
[TBL] [Abstract][Full Text] [Related]
19. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.
Barnett M; VonMuenster S; Wehring H; Popish S; McDonald K; Walker VM; Perry P
Ann Clin Psychiatry; 2010 Feb; 22(1):9-18. PubMed ID: 20196978
[TBL] [Abstract][Full Text] [Related]
20. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications.
Panagiotopoulos C; Ronsley R; Davidson J
Can J Psychiatry; 2009 Nov; 54(11):743-9. PubMed ID: 19961662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
